Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:MARK3-MIA2

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: MARK3-MIA2
	FusionPDB ID: 51772
	FusionGDB2.0 ID: 51772
		Hgene	Tgene
	Gene symbol	MARK3	MIA2
	Gene ID	4140	387885
	Gene name	microtubule affinity regulating kinase 3	cilia and flagella associated protein 73
	Synonyms	CTAK1\|KP78\|PAR1A\|Par-1a\|VIPB	CCDC42B\|MIA2
	Cytomap	14q32.32-q32.33	12q24.13
	Type of gene	protein-coding	protein-coding
	Description	MAP/microtubule affinity-regulating kinase 3C-TAK1ELKL motif kinase 2EMK-2cdc25C-associated protein kinase 1protein kinase STK10ser/Thr protein kinase PAR-1serine/threonine-protein kinase p78	cilia- and flagella-associated protein 73coiled-coil domain containing 42Bcoiled-coil domain-containing protein 42B
	Modification date	20200313	20200313
	UniProtAcc	P27448 Main function of 5'-partner protein: FUNCTION: Serine/threonine-protein kinase (PubMed:23666762). Involved in the specific phosphorylation of microtubule-associated proteins for MAP2 and MAP4. Phosphorylates the microtubule-associated protein MAPT/TAU (PubMed:23666762). Phosphorylates CDC25C on 'Ser-216'. Regulates localization and activity of some histone deacetylases by mediating phosphorylation of HDAC7, promoting subsequent interaction between HDAC7 and 14-3-3 and export from the nucleus (PubMed:16980613). Negatively regulates the Hippo signaling pathway and antagonizes the phosphorylation of LATS1. Cooperates with DLG5 to inhibit the kinase activity of STK3/MST2 toward LATS1 (PubMed:28087714). {ECO:0000269\|PubMed:16980613, ECO:0000269\|PubMed:23666762, ECO:0000269\|PubMed:28087714}.	Q96PC5 Main function of 5'-partner protein: FUNCTION: Plays a role in the transport of cargos that are too large to fit into COPII-coated vesicles and require specific mechanisms to be incorporated into membrane-bound carriers and exported from the endoplasmic reticulum (PubMed:27138255, PubMed:21525241, PubMed:25202031, PubMed:27170179). Plays a role in the secretion of lipoproteins, pre-chylomicrons and pre-VLDLs, by participating in their export from the endoplasmic reticulum (PubMed:27138255). Thereby, may play a role in cholesterol and triglyceride homeostasis (By similarity). Required for collagen VII (COL7A1) secretion by loading COL7A1 into transport carriers and recruiting PREB/SEC12 at the endoplasmic reticulum exit sites (PubMed:21525241, PubMed:25202031, PubMed:27170179). {ECO:0000250\|UniProtKB:Q91ZV0, ECO:0000269\|PubMed:21525241, ECO:0000269\|PubMed:25202031, ECO:0000269\|PubMed:27138255, ECO:0000269\|PubMed:27170179}.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000216288, ENST00000303622, ENST00000335102, ENST00000416682, ENST00000429436, ENST00000440884, ENST00000553942, ENST00000561071,	ENST00000280082, ENST00000556784,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	23 X 15 X 10=3450	13 X 9 X 4=468
	# samples	25	12
	** MAII score	log2(25/3450*10)=-3.78659636189081 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(12/468*10)=-1.96347412397489 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: MARK3 [Title/Abstract] AND MIA2 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: MARK3 [Title/Abstract] AND MIA2 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	MARK3(103852417)-MIA2(39716115), # samples:1
Anticipated loss of major functional domain due to fusion event.	MARK3-MIA2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. MARK3-MIA2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. MARK3-MIA2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. MARK3-MIA2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	MARK3	GO:0018105	peptidyl-serine phosphorylation	9543386
Hgene	MARK3	GO:0032092	positive regulation of protein binding	9543386
Hgene	MARK3	GO:0035331	negative regulation of hippo signaling	28087714
Hgene	MARK3	GO:0036289	peptidyl-serine autophosphorylation	9543386

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr14:103852417/chr14:39716115)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across MARK3 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across MIA2 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000440884	MARK3	chr14	103852417	+	ENST00000280082	MIA2	chr14	39716115	+	2724	689	638	2317	559
ENST00000440884	MARK3	chr14	103852417	+	ENST00000556784	MIA2	chr14	39716115	+	1982	689	638	1981	448
ENST00000416682	MARK3	chr14	103852417	+	ENST00000280082	MIA2	chr14	39716115	+	2663	628	577	2256	559
ENST00000416682	MARK3	chr14	103852417	+	ENST00000556784	MIA2	chr14	39716115	+	1921	628	577	1920	448
ENST00000429436	MARK3	chr14	103852417	+	ENST00000280082	MIA2	chr14	39716115	+	2596	561	510	2189	559
ENST00000429436	MARK3	chr14	103852417	+	ENST00000556784	MIA2	chr14	39716115	+	1854	561	510	1853	447
ENST00000303622	MARK3	chr14	103852417	+	ENST00000280082	MIA2	chr14	39716115	+	2575	540	489	2168	559
ENST00000303622	MARK3	chr14	103852417	+	ENST00000556784	MIA2	chr14	39716115	+	1833	540	489	1832	447
ENST00000216288	MARK3	chr14	103852417	+	ENST00000280082	MIA2	chr14	39716115	+	2256	221	170	1849	559
ENST00000216288	MARK3	chr14	103852417	+	ENST00000556784	MIA2	chr14	39716115	+	1514	221	170	1513	448
ENST00000553942	MARK3	chr14	103852417	+	ENST00000280082	MIA2	chr14	39716115	+	2131	96	45	1724	559
ENST00000553942	MARK3	chr14	103852417	+	ENST00000556784	MIA2	chr14	39716115	+	1389	96	45	1388	447
ENST00000335102	MARK3	chr14	103852417	+	ENST00000280082	MIA2	chr14	39716115	+	2086	51	0	1679	559
ENST00000335102	MARK3	chr14	103852417	+	ENST00000556784	MIA2	chr14	39716115	+	1344	51	0	1343	447

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000440884	ENST00000280082	MARK3	chr14	103852417	+	MIA2	chr14	39716115	+	0.000343727	0.9996563
ENST00000440884	ENST00000556784	MARK3	chr14	103852417	+	MIA2	chr14	39716115	+	0.000397449	0.9996026
ENST00000416682	ENST00000280082	MARK3	chr14	103852417	+	MIA2	chr14	39716115	+	0.000335604	0.9996644
ENST00000416682	ENST00000556784	MARK3	chr14	103852417	+	MIA2	chr14	39716115	+	0.000428537	0.9995715
ENST00000429436	ENST00000280082	MARK3	chr14	103852417	+	MIA2	chr14	39716115	+	0.000280957	0.9997191
ENST00000429436	ENST00000556784	MARK3	chr14	103852417	+	MIA2	chr14	39716115	+	0.000332149	0.9996679
ENST00000303622	ENST00000280082	MARK3	chr14	103852417	+	MIA2	chr14	39716115	+	0.000274985	0.99972504
ENST00000303622	ENST00000556784	MARK3	chr14	103852417	+	MIA2	chr14	39716115	+	0.000333528	0.99966645
ENST00000216288	ENST00000280082	MARK3	chr14	103852417	+	MIA2	chr14	39716115	+	0.000259115	0.9997409
ENST00000216288	ENST00000556784	MARK3	chr14	103852417	+	MIA2	chr14	39716115	+	0.000322218	0.9996778
ENST00000553942	ENST00000280082	MARK3	chr14	103852417	+	MIA2	chr14	39716115	+	0.000231147	0.9997689
ENST00000553942	ENST00000556784	MARK3	chr14	103852417	+	MIA2	chr14	39716115	+	0.000502925	0.99949706
ENST00000335102	ENST00000280082	MARK3	chr14	103852417	+	MIA2	chr14	39716115	+	0.000233388	0.99976665
ENST00000335102	ENST00000556784	MARK3	chr14	103852417	+	MIA2	chr14	39716115	+	0.000565678	0.9994343

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for MARK3-MIA2

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
MARK3	chr14	103852417	MIA2	chr14	39716115	221	17	TPLPTVNERDTENESDFLCLLGVSYT
MARK3	chr14	103852417	MIA2	chr14	39716115	51	17	TPLPTVNERDTENESDFLCLLGVSYT
MARK3	chr14	103852417	MIA2	chr14	39716115	540	17	TPLPTVNERDTENESDFLCLLGVSYT
MARK3	chr14	103852417	MIA2	chr14	39716115	561	17	TPLPTVNERDTENESDFLCLLGVSYT
MARK3	chr14	103852417	MIA2	chr14	39716115	628	17	TPLPTVNERDTENESDFLCLLGVSYT
MARK3	chr14	103852417	MIA2	chr14	39716115	689	17	TPLPTVNERDTENESDFLCLLGVSYT
MARK3	chr14	103852417	MIA2	chr14	39716115	96	17	TPLPTVNERDTENESDFLCLLGVSYT

Top

Potential FusionNeoAntigen Information of MARK3-MIA2 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

MARK3-MIA2_103852417_39716115.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
MARK3-MIA2	chr14	103852417	chr14	39716115	221	HLA-B18:01	NESDFLCL	0.9867	0.9306	12	20
MARK3-MIA2	chr14	103852417	chr14	39716115	221	HLA-B44:03	NESDFLCLL	0.9536	0.9526	12	21
MARK3-MIA2	chr14	103852417	chr14	39716115	221	HLA-B18:01	NESDFLCLL	0.8903	0.9276	12	21
MARK3-MIA2	chr14	103852417	chr14	39716115	221	HLA-B47:01	NESDFLCLL	0.8201	0.5264	12	21
MARK3-MIA2	chr14	103852417	chr14	39716115	221	HLA-B39:13	NESDFLCLL	0.4468	0.8695	12	21
MARK3-MIA2	chr14	103852417	chr14	39716115	221	HLA-B38:02	ERDTENESDF	0.8386	0.844	7	17
MARK3-MIA2	chr14	103852417	chr14	39716115	221	HLA-B38:01	ERDTENESDF	0.8133	0.8263	7	17
MARK3-MIA2	chr14	103852417	chr14	39716115	221	HLA-B39:01	ERDTENESDFL	0.9984	0.7212	7	18
MARK3-MIA2	chr14	103852417	chr14	39716115	221	HLA-B38:02	ERDTENESDFL	0.9974	0.8624	7	18
MARK3-MIA2	chr14	103852417	chr14	39716115	221	HLA-B18:01	NERDTENESDF	0.9438	0.6789	6	17
MARK3-MIA2	chr14	103852417	chr14	39716115	221	HLA-B39:08	TENESDFL	0.9762	0.7865	10	18
MARK3-MIA2	chr14	103852417	chr14	39716115	221	HLA-B39:08	NESDFLCLL	0.5163	0.6703	12	21
MARK3-MIA2	chr14	103852417	chr14	39716115	221	HLA-B18:05	NESDFLCL	0.9867	0.9306	12	20
MARK3-MIA2	chr14	103852417	chr14	39716115	221	HLA-B18:06	NESDFLCL	0.9828	0.9374	12	20
MARK3-MIA2	chr14	103852417	chr14	39716115	221	HLA-B18:03	NESDFLCL	0.9825	0.9258	12	20
MARK3-MIA2	chr14	103852417	chr14	39716115	221	HLA-B18:11	NESDFLCL	0.9147	0.886	12	20
MARK3-MIA2	chr14	103852417	chr14	39716115	221	HLA-B40:04	NESDFLCLL	0.9925	0.6966	12	21
MARK3-MIA2	chr14	103852417	chr14	39716115	221	HLA-B44:07	NESDFLCLL	0.9536	0.9526	12	21
MARK3-MIA2	chr14	103852417	chr14	39716115	221	HLA-B44:13	NESDFLCLL	0.9536	0.9526	12	21
MARK3-MIA2	chr14	103852417	chr14	39716115	221	HLA-B44:26	NESDFLCLL	0.9536	0.9526	12	21
MARK3-MIA2	chr14	103852417	chr14	39716115	221	HLA-B18:04	NESDFLCLL	0.9334	0.9341	12	21
MARK3-MIA2	chr14	103852417	chr14	39716115	221	HLA-B18:08	NESDFLCLL	0.8964	0.8997	12	21
MARK3-MIA2	chr14	103852417	chr14	39716115	221	HLA-B18:05	NESDFLCLL	0.8903	0.9276	12	21
MARK3-MIA2	chr14	103852417	chr14	39716115	221	HLA-B18:06	NESDFLCLL	0.8754	0.9346	12	21
MARK3-MIA2	chr14	103852417	chr14	39716115	221	HLA-B18:03	NESDFLCLL	0.846	0.9235	12	21
MARK3-MIA2	chr14	103852417	chr14	39716115	221	HLA-B18:11	NESDFLCLL	0.6337	0.9084	12	21
MARK3-MIA2	chr14	103852417	chr14	39716115	221	HLA-B39:31	NESDFLCLL	0.4446	0.9309	12	21
MARK3-MIA2	chr14	103852417	chr14	39716115	221	HLA-B39:02	NESDFLCLL	0.4064	0.8799	12	21
MARK3-MIA2	chr14	103852417	chr14	39716115	221	HLA-B40:04	TENESDFLCL	0.9642	0.6568	10	20
MARK3-MIA2	chr14	103852417	chr14	39716115	221	HLA-B38:05	ERDTENESDF	0.8133	0.8263	7	17
MARK3-MIA2	chr14	103852417	chr14	39716115	221	HLA-B39:11	ERDTENESDFL	0.997	0.5081	7	18
MARK3-MIA2	chr14	103852417	chr14	39716115	221	HLA-B18:05	NERDTENESDF	0.9438	0.6789	6	17

Top

Potential FusionNeoAntigen Information of MARK3-MIA2 in HLA II

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene

Hchr

Hbp

Tgene

Tchr

Tbp

HLA II

FusionNeoAntigen peptide

Neoantigen start (at BP 13)

Neoantigen end (at BP 13)

Top

Fusion breakpoint peptide structures of MARK3-MIA2

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
6144	NERDTENESDFLCL	MARK3	MIA2	chr14	103852417	chr14	39716115	221

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of MARK3-MIA2

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	6144	NERDTENESDFLCL	-7.93306	-8.12316
HLA-B14:02	3BVN	6144	NERDTENESDFLCL	-7.77997	-8.54597
HLA-B52:01	3W39	6144	NERDTENESDFLCL	-7.23925	-8.00525
HLA-B52:01	3W39	6144	NERDTENESDFLCL	-7.15693	-7.34703
HLA-A24:02	5HGA	6144	NERDTENESDFLCL	-7.43128	-7.62138
HLA-A24:02	5HGA	6144	NERDTENESDFLCL	-6.21273	-6.97873
HLA-B44:05	3DX8	6144	NERDTENESDFLCL	-6.84125	-7.03135
HLA-B44:05	3DX8	6144	NERDTENESDFLCL	-3.24208	-4.00808

Top

Vaccine Design for the FusionNeoAntigens of MARK3-MIA2

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
MARK3-MIA2	chr14	103852417	chr14	39716115	10	18	TENESDFL	ACTGAAAACGAATCTGACTTTCTT
MARK3-MIA2	chr14	103852417	chr14	39716115	10	20	TENESDFLCL	ACTGAAAACGAATCTGACTTTCTTTGTCTT
MARK3-MIA2	chr14	103852417	chr14	39716115	12	20	NESDFLCL	AACGAATCTGACTTTCTTTGTCTT
MARK3-MIA2	chr14	103852417	chr14	39716115	12	21	NESDFLCLL	AACGAATCTGACTTTCTTTGTCTTCTT
MARK3-MIA2	chr14	103852417	chr14	39716115	6	17	NERDTENESDF	AATGAACGAGACACTGAAAACGAATCTGACTTT
MARK3-MIA2	chr14	103852417	chr14	39716115	7	17	ERDTENESDF	GAACGAGACACTGAAAACGAATCTGACTTT
MARK3-MIA2	chr14	103852417	chr14	39716115	7	18	ERDTENESDFL	GAACGAGACACTGAAAACGAATCTGACTTTCTT

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene

Hchr

Hbp

Tchr

Tbp

Start in +/-13AA

End in +/-13AA

FusionNeoAntigen peptide

FusionNEoAntigen RNA sequence

Top

Information of the samples that have these potential fusion neoantigens of MARK3-MIA2

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
BRCA	MARK3-MIA2	chr14	103852417	ENST00000216288	chr14	39716115	ENST00000280082	TCGA-B6-A0I9-01A

Top

Potential target of CAR-T therapy development for MARK3-MIA2

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Tgene

MIA2

chr14:103852417

chr14:39716115

ENST00000280082

606_626

655.0

Intramembrane

Ontology_term=ECO:0000255

Tgene

MIA2

chr14:103852417

chr14:39716115

ENST00000556784

606_626

542.0

Intramembrane

Ontology_term=ECO:0000255

Tgene

MIA2

chr14:103852417

chr14:39716115

ENST00000280082

647_667

655.0

Transmembrane

Helical

Tgene

MIA2

chr14:103852417

chr14:39716115

ENST00000556784

647_667

542.0

Transmembrane

Helical

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to MARK3-MIA2

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to MARK3-MIA2

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)